Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M197,378Revenue (TTM) $M49,778Net Margin (%)13.6Altman Z-Score2.6
Enterprise Value $M217,201EPS (TTM) $2.8Operating Margin %17.0Piotroski F-Score5
P/E(ttm)29.8Beneish M-Score-2.7Pre-tax Margin (%)15.6Higher ROA y-yN
Price/Book2.810-y EBITDA Growth Rate %-2.3Quick Ratio0.7Cash flow > EarningsY
Price/Sales4.05-y EBITDA Growth Rate %-4.1Current Ratio0.9Lower Leverage y-yN
Price/Free Cash Flow22.8y-y EBITDA Growth Rate %-16.8ROA % (ttm)5.1Higher Current Ratio y-yY
Dividend Yield %3.3PEG--ROE % (ttm)9.0Less Shares Outstanding y-yY
Payout Ratio %98.0Shares Outstanding M2,381ROIC % (ttm)7.6Gross Margin Increase y-yN

Gurus Latest Trades with NVS

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVSKen Fisher 2016-03-31 Add0.01%$71.11 - $86.21
($76.1)
$ 83.029%Add 1.59%6,287,099
NVSTweedy Browne 2016-03-31 Reduce-0.01%$71.11 - $86.21
($76.1)
$ 83.029%Reduce -1.87%237,664
NVSTom Gayner 2016-03-31 Buy 0.01%$71.11 - $86.21
($76.1)
$ 83.029%New holding3,700
NVSJohn Rogers 2016-03-31 Add$71.11 - $86.21
($76.1)
$ 83.029%Add 18.01%13,296
NVSMario Gabelli 2016-03-31 Reduce$71.11 - $86.21
($76.1)
$ 83.029%Reduce -7.10%6,865
NVSDodge & Cox 2016-03-31 Reduce$71.11 - $86.21
($76.1)
$ 83.029%Reduce -0.12%45,054,916
NVSDodge & Cox 2015-12-31 Reduce-0.06%$83.96 - $95.03
($88.53)
$ 83.02-6%Reduce -1.35%45,107,085
NVSTweedy Browne 2015-12-31 Reduce-0.02%$83.96 - $95.03
($88.53)
$ 83.02-6%Reduce -2.74%242,201
NVSKahn Brothers 2015-12-31 Reduce-0.02%$83.96 - $95.03
($88.53)
$ 83.02-6%Reduce -3.15%27,643
NVSJohn Rogers 2015-12-31 Buy 0.01%$83.96 - $95.03
($88.53)
$ 83.02-6%New holding11,267
NVSKen Fisher 2015-12-31 Add0.01%$83.96 - $95.03
($88.6)
$ 83.02-6%Add 0.92%6,188,893
NVSMario Gabelli 2015-12-31 Reduce$83.96 - $95.03
($88.53)
$ 83.02-6%Reduce -1.99%7,390
NVSDodge & Cox 2015-09-30 Reduce-0.2%$89.52 - $106.12
($99.32)
$ 83.02-16%Reduce -4.68%45,723,035
NVSKen Fisher 2015-09-30 Add0.02%$89.52 - $106.12
($99.32)
$ 83.02-16%Add 1.28%6,132,211
NVSKahn Brothers 2015-09-30 Add0.01%$89.52 - $106.12
($99.32)
$ 83.02-16%Add 1.42%28,543
NVSTweedy Browne 2015-09-30 Reduce-0.01%$89.52 - $106.12
($99.32)
$ 83.02-16%Reduce -2.04%249,022
NVSMario Gabelli 2015-09-30 Reduce$89.52 - $106.12
($99.32)
$ 83.02-16%Reduce -9.48%7,540
NVSDodge & Cox 2015-06-30 Reduce-0.19%$98.34 - $105.5
($102.32)
$ 83.02-19%Reduce -4.12%47,970,345
NVSKahn Brothers 2015-06-30 Reduce-0.05%$98.34 - $105.5
($102.32)
$ 83.02-19%Reduce -9.12%28,143
NVSTweedy Browne 2015-06-30 Reduce-0.02%$98.34 - $105.5
($102.32)
$ 83.02-19%Reduce -2.31%254,217
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVS is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


NVS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Novartis Bioventures Ltd10% Owner 2014-09-22Buy325,000$15453.47view

Quarterly/Annual Reports about NVS:

    News about NVS:

    Articles On GuruFocus.com
    Roche Holdings Definitely Not a Lumbering Giant Jul 11 2016 
    Causeway International Value Fund May Performance Review Jul 08 2016 
    Pfizer, Merck, Other Big Pharmas Likely to Acquire Marijuana-Based Drug Companies Jun 13 2016 
    Samuel Isaly Trades in Health Care Stocks in 1st Quarter Apr 27 2016 
    Does Biotech’s Recent Bounce Have Legs? Apr 22 2016 
    Dividend and Value Opportunities in the Large-Cap Pharmaceutical Space Apr 05 2016 
    Dan Loeb's Third Point Portfolio Highly Concentrated Apr 01 2016 
    Daniel Loeb's Third Point Portfolio Highly Concentrated Mar 31 2016 
    Valeant's Share Price Continues to Decline Feb 05 2016 
    10 Fund Managers Are Totally Wrong on GlaxoSmithKline Jan 26 2016 

    More From Other Websites
    Novartis AG :NVS-US: Earnings Analysis: Q2, 2016 By the Numbers : July 26, 2016 Jul 26 2016
    What Do the Recent Changes in Novartis’s 2Q16 Valuation Tell Us? Jul 26 2016
    How Do the Majority of Analysts Rate Novartis after 2Q16? Jul 25 2016
    Eli Lilly, J&J, Novo Battle Diabetes -- And Each Other Jul 22 2016
    GlaxoSmithKline Segments That Drive Company’s Rising Revenues Jul 22 2016
    What Role Did Innovative Medicines Play in Novartis’s 2Q16 Earnings? Jul 22 2016
    What Are Lilly’s 2Q16 Estimates and Expectations for Elanco? Jul 22 2016
    Research Reports on Facebook (FB), Tesla (TSLA) & Others Jul 21 2016
    Inside the Foreign Exchange Impact on Novartis’s Growth in 2Q16 Jul 21 2016
    How Did Novartis’s 2Q16 Earnings Stand up to Analyst Estimates? Jul 21 2016
    Opioid Addiction: What To Do When A Loved One Is Hooked, According To Science Jul 21 2016
    Novartis (NVS) Tops Q2 Earnings & Sales, Expenses to Grow Jul 20 2016
    Pricing dispute hits supply of TB drugs in Pakistan Jul 19 2016
    Amgen Finally Scores a Win in Its Big Copycat Drug Battle With Novartis Jul 19 2016
    Novartis Shares Slip Tuesday on Falling Profit Jul 19 2016
    What Lilly Expects for Revenue Growth in 2Q16 Jul 19 2016
    Novartis Set To Become Biosimilar Pioneer By 2020 Jul 19 2016
    Novartis Set To Become Biosimilar Pioneer By 2020 Jul 19 2016
    ETF’s with exposure to Novartis AG : July 19, 2016 Jul 19 2016
    Novartis profit slips as generic drug competition hits sales Jul 19 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)